# Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product

- URL: https://theranews.net/blog/2026-03-18-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-receives-fda-feedback-on-bi-0bdaef/
- Published: 2026-03-18
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: menafn
- Original report: https://menafn.com/1110873691/Biomednewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Feedback-On-Bioequivalence-For-Ketamine-Product
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA's Bioequivalence Program stating no bioequivalence deficiencies were identified at ...

---
![Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product](/uploads/news-images/biomednewsbreaks-nrx-pharmaceuticals-inc-nasd-20260318110126.jpg)

---
*Originally reported by menafn. [Read more](https://menafn.com/1110873691/Biomednewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Feedback-On-Bioequivalence-For-Ketamine-Product)*

---

*Source: [https://menafn.com/1110873691/Biomednewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Feedback-On-Bioequivalence-For-Ketamine-Product](https://menafn.com/1110873691/Biomednewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Receives-FDA-Feedback-On-Bioequivalence-For-Ketamine-Product)*